ROS1阳性非小细胞肺癌靶向治疗的研究进展

Research progress on targeted treatment in ROS1-positive non-small cell lung cancer

ROS1融合基因作为非小细胞肺癌(NSCLC)分子靶向治疗又一新的潜力靶点,近年来,越来越多的学者将焦点转移到ROS1融合基因上.体外实验和临床研究结果均显示,间变性淋巴瘤激酶(ALK)抑制剂对ROS1阳性NSCLC患者具有明显的抗肿瘤活性,但仍不可避免出现耐药.目前ROS1阳性NSCLC尚无标准化诊疗方案.因此,针对ROS1的ALK抑制剂的进一步研究至关重要,可为NSCLC患者靶向治疗和研究提供新的治疗思路.

ROS1 fusion gene is a new potential target for molecular targeted therapy of non-small cell lung cancer(NSCLC).In recent years,more and more scholars focus on ROS1 fusion gene.The results of in vitro experiments and clinical research both show that anaplastic lymphoma kinase(ALK)inhibitors have potent anti-tumor activity in ROS1-positive NSCLC patients,but drug resistance is still inevitable.At present,there is no standardized diagnosis and treatment path for ROS1-positive NSCLC.Therefore,further study on the ALK inhibitors of ROS1 is very important,which can provide a new therapeutic idea for targeted treatment and research of NSCLC patients.